



ASH 2021 abstracts

What's hot in MPN?

Brought to you by SES



63rd ASH Annual Meeting and Exposition

Top abstracts in MPN

- To help navigate the exciting content being presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub Steering Committee members have provided their recommendations of the top abstracts to look for in the following categories: clinical trial updates from JAK inhibitors and non-JAK inhibitors; rare MPN subtypes; prophylaxis and management of vascular events in patients with MPN; basic and translational data; COVID-19 and clinical research data in MPN.



Clinical trial updates – JAK inhibitors

Oral sessions and poster presentations

Abstract	Type	Title	Date/Time
389	Oral session	<u>Safety and tolerability of fedratinib (FEDR), an oral inhibitor of Janus kinase 2 (JAK2), in patients with intermediate- or high-risk myelofibrosis (MF) previously treated with ruxolitinib (rux): results from the phase 3b freedom trial</u>	Sunday, December 12, 10:30 AM
2576	Poster	<u>Spleen and symptom responses with fedratinib (FEDR) in patients with myelofibrosis (MF) and substantial splenomegaly</u>	Sunday, December 12, 6:00–8:00 PM
3628	Poster	<u>The impact of pacritinib on myelofibrosis symptoms in patients with moderate and severe thrombocytopenia: A retrospective analysis of patients in the Persist-2 study</u>	Monday, December 13, 6:00–8:00 PM
3639	Poster	<u>A retrospective head-to-head comparison between pacritinib and ruxolitinib in patients with myelofibrosis and moderate to severe thrombocytopenia</u>	Monday, December 13, 6:00–8:00 PM
3640	Poster	<u>Safety analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia</u>	Monday, December 13, 6:00–8:00 PM

Clinical trial updates – Non-JAK inhibitors

Oral sessions and poster presentations

Abstract	Type	Title	Date/Time
144	Oral session	<u>Final results of a phase 2 study of sotatercept (ACE-011) for anemia of MPN-associated myelofibrosis</u>	Saturday, December 11, 1:15 PM
388	Oral session	<u>Rusfertide (PTG-300) controls hematocrit levels and essentially eliminates phlebotomy requirement in polycythemia vera patients</u>	Sunday, December 12, 10:15 AM
390	Oral session	<u>Rusfertide (PTG-300) induction therapy rapidly achieves hematocrit control in polycythemia vera patients without the need for therapeutic phlebotomy</u>	Sunday, December 12, 10:45 AM
2568	Poster	<u>Disease-modifying potential of BET inhibitor pelabresib (CPI-0610) as demonstrated by improvements in bone marrow function and clinical activity in patients with myelofibrosis – Preliminary data</u>	Sunday, December 12, 6:00–8:00 PM
3581	Poster	<u>Potential disease-modifying activity of navtemadlin (KRT-232), a first-in-class MDM2 inhibitor, correlates with clinical benefits in relapsed/refractory myelofibrosis (MF)</u>	Monday, December 13, 6:00–8:00 PM

Management of MPN accelerated and blast phase

Oral sessions and poster presentations

Abstract	Type	Title	Date/Time
314	Oral session	<u>Reduced intensity stem cell transplantation for accelerated-phase myelofibrosis</u>	Saturday, December 11, 4:15 PM
385	Oral session	<u>A phase 2 study of pemigatinib (FIGHT-203; INCB054828) in patients with myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLN^{FGFR1})</u>	Sunday, December 12, 9:30 AM
2569	Poster	<u>Efficacy of HMA +/- venetoclax or intensive chemotherapy in blast-phase myeloproliferative neoplasms</u>	Sunday, December 12, 6:00–8:00 PM

The prophylaxis and management of vascular events in patients with MPN

Oral sessions and poster presentations

Abstract	Type	Title	Date/Time
236	Oral session	<u>The interaction between IPSS score and JAK2 mutation identifies patients at different vascular risk in primary myelofibrosis</u>	Saturday, December 11, 2:15 PM
237	Oral session	<u>A JAK2V617F variant allele frequency greater than 50% identifies patients with polycythemia vera at high risk for venous thrombosis</u>	Saturday, December 11, 2:30 PM
238	Oral session	<u>A globally applicable “triple AAA” risk model for essential thrombocythemia based on age, absolute neutrophil count, and absolute lymphocyte count</u>	Saturday, December 11, 2:45 PM
239	Oral session	<u>A real-world evaluation of the association between elevated blood counts and thrombotic events in polycythemia vera (analysis of data from the REVEAL study)</u>	Saturday, December 11, 3:00 PM
1499	Poster	<u>Neutrophil-to-lymphocyte ratio (NLR) is a risk factor for venous thrombosis in polycythemia vera</u>	Saturday, December 11, 5:30–7:30 PM
2575	Poster	<u>Normal life expectancy for polycythemia vera patients is possible</u>	Sunday, December 12, 6:00–8:00 PM
3619	Poster	<u>A novel machine learning-derived dynamic scoring system predicts risk of thrombosis in polycythemia vera (PV) patients</u>	Monday, December 13, 6:00–8:00 PM
3651	Poster	<u>Deciphering the individual contribution of absolute neutrophil, lymphocyte and monocyte counts to thrombosis risk in patients with myeloproliferative neoplasms</u>	Monday, December 13, 6:00–8:00 PM

Basic and translational data in MPN

Oral sessions

Abstract	Type	Title	Date/Time
55	Oral session	<u>DUSP6 mediates resistance to JAK2 inhibition and drives myeloproliferative neoplasm disease progression</u>	Saturday, December 11, 9:30 AM
56	Oral session	<u>Single cell mutation analysis delineates clonal architecture in leukemic transformation of myeloproliferative neoplasms</u>	Saturday, December 11, 9:45 AM
57	Oral session	<u>Single-cell multi-omics reveals that pegylated interferon-alfa treatment differentially redirects mutated and wildtype hematopoietic cell differentiation trajectories in CALR-mutated essential thrombocythemia (ET) patients</u>	Saturday, December 11, 10:00 AM
58	Oral session	<u>Whole-genome CRISPR screening identifies <i>n</i>-glycosylation as an essential pathway and a potential novel therapeutic target in CALR-mutant MPN</u>	Saturday, December 11, 10:15 AM
60	Oral session	<u>IL13 contributes to fibrotic progression of the myeloproliferative neoplasms</u>	Saturday, December 11, 10:45 AM
625	Oral session	<u>HMGA1 chromatin regulators drive progression in myeloproliferative neoplasms through epigenetic rewiring to induce networks involved in GATA2 and proliferation</u>	Monday, December 13, 10:30 AM
627	Oral session	<u>Hematopoietic stem and progenitor cell fitness as a novel prognostic and monitoring biomarker for JAK2V617F myeloproliferative neoplasms (MPNs)</u>	Monday, December 13, 11:00 AM

COVID-19 and MPN

Oral sessions

Abstract	Type	Title	Date/Time
315	Oral session	<u>Second <i>versus</i> first wave of COVID-19 in patients with MPN</u>	Saturday, December 11, 4:30 PM
316	Oral session	<u>Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neoplasm patients</u>	Saturday, December 11, 4:45 PM

Sessions to look out for

Education session, satellite symposium, scientific workshop, and plenary scientific session

Type	Title	Date/Time
Education Session	<u>MPN: New directions</u> <ul style="list-style-type: none">○ <i>MPN and thrombosis was hard enough ... now there is COVID thrombosis too.</i>○ <i>Novel therapies vs allotransplant in myelofibrosis: Who, when, how?</i>○ <i>Running interferon interference in treating PV/ET: Meeting unmet needs.</i>	Tuesday, December 7, 4:00–4:45 PM
Friday Satellite Symposium	<u>Diagnosis and treatment of MF and PV: Where are we and where are we going?</u>	Friday, December 10, 11:00 AM–2:00 PM
Scientific Workshop	<u>Myeloid malignancy risk prediction and assessment</u> <i>A family registry of MPN and a potential predictive phenotype.</i>	Friday, December 10, 2:03 PM–2:49 PM
Plenary Scientific Session #3	<u>Single-cell multi-omics reveals the genetic, cellular and molecular landscape of <i>TP53</i> mutated leukemic transformation in MPN</u>	Sunday, December 12, 2:00 PM–4:00 PM



Thank you

mpn-hub.com

 **Scientific Education Support**